Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
CASE 13815   A phase II trial of weight-based dosing for dense weekly paclitaxel and carboplatin in overweight patients with a BSA>2.0. Fairview, Hillcrest, Main Campus Phase 2Gynecologic
GOG 0225IRB 12-869 Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival? Fairview, Hillcrest, Main CampusStage 2, Stage 3, Stage 4 Fallopian Tube, Gynecologic, Ovarian, Peritoneal
GOG 0264CC906 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advance Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary Fairview, Hillcrest, Main CampusRecurrent/Relapsed, Stage 2, Stage 3, Stage 4Phase 2Gynecologic, Ovarian
GOG 0274CC00194 A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone. Fairview, Hillcrest, Main CampusStage 1, Stage 2, Stage 3, Stage 4Phase 3Cervical, Gynecologic
GOG 0279 12-1287 A Phase II Trial Evaluating Cisplatin and Gemcitabine Concurrent with Intensity-Modulated Radiation Therapy (IMRT) for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva (Neil S Horowitz) Fairview, Hillcrest, Main Campus Phase 2Gynecologic, Vulva
GOG 300515-866 A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrentand Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous EpithelialOvarian, Fallopian Tube, or Primary Peritoneal Cancer Fairview, Hillcrest, Main CampusStage 2, Stage 3, Stage 4Phase 3Fallopian Tube, Gynecologic, Ovarian, Peritoneal
JAN 1814 14-711 A Randomized, Open-Label Study Comparing the Combination of YONDELIS, and DOXIL/CAELYX,With DOXIL,/CAELYX, Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Fairview, Hillcrest, Main CampusRecurrent/RelapsedPhase 3Fallopian Tube, Gynecologic, Ovarian, Peritoneal
MORAb-003-011 15-298 MORAb-003-011, A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Fairview, Hillcrest, Main CampusRecurrent/RelapsedPhase 2Fallopian Tube, Gynecologic, Ovarian, Peritoneal
NRG-GY004 16-360 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Fairview, Hillcrest, Main Campus Phase 3Fallopian Tube, Gynecologic, Ovarian, Peritoneal
NRG-GY005 16-395 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Fairview, Hillcrest, Main CampusRecurrent/RelapsedPhase 2, Phase 3Fallopian Tube, Gynecologic, Ovarian, Peritoneal
NRG-GY006 16-359 A Randomized Phase II Trail of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Fairview, Hillcrest, Main CampusStage 1, Stage 2, Stage 3, Stage 4Phase 2Cervical, Gynecologic, Uterine, Vaginal
NRG-GY007 16-877 A Phase I/II Study of Ruxolitnib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Fairview, Hillcrest, Main CampusStage 3, Stage 4Phase 1, Phase 2Fallopian Tube, Gynecologic, Ovarian, Peritoneal

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.